-
Neoangiogenesis and blood-brain barrier in L-DOPA-induced dyskinesia
… This grant builds upon the research from a prior grant: Neoangiogenesis and Blood-Brain Barrier … mechanistic targets for Parkinson´s therapy. Our results from the pre-clinical model of levodopa-induced dyskinesia …
-
Testing of Davunetide for Intranasal Administration in Pre-clinical Models Over Expressing Alpha-synuclein
… the symptoms of the disease requires drug treatment data from an pre-clinical model such as this which recapitulates … behavior and the key pathologies responsible. The findings from the current study show davunetide to reduce …
-
Attenuation of Neuroinflammation by Brain-targeted Liposomal Methylprednisolone (2B3-201) in Two Pre-clinical Models of Parkinson's Disease
… be detected with automated longitudinal behavioral testing from age 20 to 48 weeks. Treatment with 2B3-201 will be … effect on the levels of one of the metabolites formed from dopamine, while neuronal cell death remained unchanged. …
-
Effect of Novel Neuronal Nicotinic Receptor Compounds on Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
… This grant builds upon the research from a prior grant: Prospective study of nonsteroidal … in PD. Thus, their translational value is high. Results from these studies will provide a firm basis for the …
-
Novel Neuroprotective Cell-Penetrating Peptides
… disease. We found a cell-penetrating octapeptide from MANF that protects the cultured dopaminergic neurons from apoptotic death. The small size and cell-penetrating …
-
Gene Therapy to Restore Protein Imbalance in Parkinson's Disease
… is characterized by impairment of motor control as a result from extensive neuron death. The primary mechanism … in PD remains unknown; however, clues have been obtained from families who have a genetic form of PD that is …